Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bridge Biotherapeutics Inc.

www.bridgebiorx.com

Latest From Bridge Biotherapeutics Inc.

Tech Transfer Roundup: Universities And Biotechs Continue To Look For Ways To Combat COVID-19

AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.

Deals Coronavirus COVID-19

iOnctura Develops Next-Generation PI3K-Delta Inhibitors For Cancer

Emerging Company Profile: Switzerland’s iOnctura is working on PI3K-delta inhibitors and autotaxin inhibitors that have potential in solid tumors and cancer-associated fibrosis.

StartUps and SMEs ImmunoOncology

Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Vaccine Development

Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.

Deals Coronavirus COVID-19

Key Words For Korean Pharma In 2010s: Novelty, Open Innovation, Global Markets

From being generics-focused to becoming innovators and leaders in biosimilars, Scrip takes a look at how the Korean pharma sector and environment have evolved over the past 10 years.

South Korea Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Hepatic (Liver)
  • Inflammation
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Bridge Biotherapeutics Inc.
  • Senior Management
  • James Jungkue Lee, CEO
    Taeksang Park, VP, CFO
    Sang-Uk Kang, SVP, R&D
  • Contact Info
  • Bridge Biotherapeutics Inc.
    253 Pangyo-ro, Bundang-gu, Ste.903-2
    Bldg. B
    Seongnam, 13486
    South Korea
UsernamePublicRestriction

Register